Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +20

Charles River Laboratories stock falls 2.73 percent after Q2 results

Earnings report Guidance raised AI-generated analysis

📉 Charles River Laboratories stock fell 2.73% to $277.33 following Q2 results where revenue dropped 2.7% year-over-year to $1 billion.

💰 Non-GAAP EPS decreased 3.2% to $3.02, though the result exceeded analyst consensus estimates by 11.0%.

📉 GAAP earnings showed a loss of $0.03 per share due to a $63.7 million charge primarily tied to divestitures.

🔬 The Discovery and Safety Assessment segment generated $606.5 million in revenue with a 20.5% GAAP operating margin.

🏭 Manufacturing revenue declined 6.3% to $188.1 million but saw its non-GAAP operating margin expand to 37.8%.

📈 The DSA segment reported a net book-to-bill ratio of 1.19 and sequential booking growth of 13%.

🚀 Management raised the full-year 2026 non-GAAP EPS guidance range to $11.15-$11.45 from the prior $10.80-$11.30.

📉 Revenue guidance was revised to a decline of 3.5% to 2.5%, reflecting near-term top-line headwinds.

📊 The company's market capitalization stood at approximately $13.36 billion as of September 23, 2026.

Bullish Signals
  • Management raised its full-year 2026 non-GAAP EPS guidance to a range of $11.15-$11.45, indicating confidence in future profitability despite near-term revenue challenges.
  • The Discovery and Safety Assessment segment achieved a net book-to-bill ratio of 1.19 with sequential booking growth of 13%, signaling strong demand that should rebuild backlog.
  • Non-GAAP EPS of $3.02 exceeded analyst consensus estimates by 11.0%, demonstrating that adjusted operating performance remains robust above market expectations.
  • The Manufacturing segment expanded its non-GAAP operating margin to 37.8% despite a revenue decline, showcasing improved pricing power or cost efficiency.
Risk Factors
  • Q2 revenue declined 2.7% year-over-year to $1 billion, indicating ongoing top-line pressure in the current market environment.
  • GAAP earnings resulted in a loss of $0.03 per share due to a significant $63.7 million charge related to divestitures.
  • The Discovery and Safety Assessment segment revenue fell 1.9% year-over-year, contributing to the overall top-line weakness.
Full Analysis
Charles River Laboratories International reported second-quarter 2026 results that saw its stock fall 2.73% to close at $277.33 on the NYSE. While Q2 revenue declined 2.7% year-over-year to $1 billion, organic revenue growth was a modest 0.1%. Non-GAAP earnings per share dropped 3.2% to $3.02, though this figure still beat analyst consensus by 11.0%. The GAAP result showed a loss of $0.03 per share, primarily driven by a $63.7 million charge related to divestitures. Operating performance varied significantly across business segments during the quarter. The Discovery and Safety Assessment (DSA) segment generated $606.5 million in revenue, down 1.9% year-over-year, yet achieved a GAAP operating margin of 20.5%. Conversely, the Manufacturing segment saw revenue decline by 6.3% to $188.1 million but expanded its non-GAAP operating margin to 37.8%, highlighting divergent profitability trends within the company's portfolio. Despite the near-term stock decline and top-line contraction, management raised its full-year 2026 non-GAAP earnings outlook following strong booking activity. At the Global Healthcare Conference, the DSA segment reported a net book-to-bill ratio of 1.19 and sequential booking growth of 13%. This indicates that bookings are exceeding revenue, which should help rebuild backlog levels over time, although management characterized the recovery as gradual rather than an immediate acceleration. The market is currently weighing conflicting signals regarding Charles River Laboratories' trajectory. The stock remains 8.56% below its 52-week high of $303.31, reflecting investor caution on the revenue decline and GAAP loss. However, the raised EPS guidance and robust booking metrics suggest a potential recovery case that hinges on successfully converting current bookings into future revenue streams in the coming quarters.